major amputation

The SWEDEPAD 1 trial evaluated paclitaxel-coated versus uncoated devices for infrainguinal revascularisation in chronic limb-threatening ischaemia, finding no significant reduction in major amputations or mortality over a median 2.7-year follow-up.